Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation in Patients With Hypercapnic COPD (COPD)
2019年4月24日 更新者:Xiangya Hospital of Central South University
Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in Patients With Hypercapnic COPD,a Randomized Controlled Trial
To test if high-flow conditioned oxygen therapy is noninferior to NIV for preventing postextubation respiratory failure and reintubation in patients with hypercapnic COPD, investigators plan to conduct the participants level, 1:1 randomized trial at the respiratory ICU.
Participants were randomized to undergo either high-flow conditioned oxygen therapy or noninvasive mechanical ventilation after extubation.
Primary outcomes were reintubation and postextubation respiratory failure within 72 hours.
Secondary outcomes included length of RICU stay after extubation and mortality; partial pressure of arterial carbon dioxide.
研究概览
研究类型
介入性
注册 (实际的)
100
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Hunan
-
Changsha、Hunan、中国、410008
- Xiangya Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Clinical diagnosis of AECOPD
- Extubation must be performed after 48 hours of invasive ventilation
- Must be treated sequentially with HFNC or NIV after extubation
- PaCO2≥50mmHg when extubation
- Positive End Expiratory Pressure (PEEP) ≤8cmH2O (1cmH2O=0.098 kPa) when extubation
Exclusion Criteria:
- Do-not-intubate
- Tracheostomies
- Accidental extubation
- Self-extubation
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
其他:High-Flow Nasal Cannula
High-flow oxygen was applied immediately after extubation through specific nasal cannula.
|
High-flowoxygenwas applied immediately after extubation through specific nasal cannula.
Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%.
After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.
|
其他:Noninvasive Ventilation
Noninvasive Ventilation was applied immediately after extubation.
|
Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation.
Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation [SaO2] 92%, with pH of 7.35).
The FIO2 was adjusted to maintain SPO2 at less than 92%.
Sedatives to increase tolerance to NIV were not allowed.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Rate of reintubation
大体时间:Within 72 hours after extubation
|
The proportion of patients requiring reintubation within 72 hours after extubation
|
Within 72 hours after extubation
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
RICU length of stay after extubation
大体时间:From date of extubation until the date of discharging from the RICU up to 28 days
|
Length of time from extubation to discharging from the RICU
|
From date of extubation until the date of discharging from the RICU up to 28 days
|
Mortality
大体时间:Within 28 days after extubation
|
Mortality after extubation
|
Within 28 days after extubation
|
Partial pressure of arterial carbon dioxide
大体时间:Within 24 hours before extubation and within 72 hours after extubation
|
Partial pressure of arterial carbon dioxide tested at the appointed time
|
Within 24 hours before extubation and within 72 hours after extubation
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2016年5月1日
初级完成 (预期的)
2019年12月31日
研究完成 (预期的)
2019年12月31日
研究注册日期
首次提交
2019年4月13日
首先提交符合 QC 标准的
2019年4月24日
首次发布 (实际的)
2019年4月26日
研究记录更新
最后更新发布 (实际的)
2019年4月26日
上次提交的符合 QC 标准的更新
2019年4月24日
最后验证
2018年12月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
慢性阻塞性肺病的临床试验
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...完全的
-
Virginia Commonwealth UniversityFisher and Paykel Healthcare完全的
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom; Royal Free Hampstead...未知
-
AstraZeneca完全的
-
Chiesi Farmaceutici S.p.A.完全的中度至重度慢性阻塞性肺疾病 (COPD)保加利亚, 德国, 匈牙利, 波兰, 俄罗斯联邦, 英国
High-FlowNasal Cannula的临床试验
-
University Hospital Inselspital, Berne招聘中青光眼 | 黄斑变性 | 葡萄膜炎 | 糖尿病性视网膜病变 | 糖尿病性黄斑水肿 | 黄斑水肿 | 视网膜静脉阻塞 | 视神经疾病 | 视网膜脱离 | 黄斑部疾病 | 视网膜疾病 | 视网膜新生血管 | 视网膜动脉阻塞 | 高血压性视网膜病变 | 视网膜水肿 | 视网膜营养不良瑞士
-
The Hong Kong Polytechnic UniversityYan Chai Hospital Social Services主动,不招人
-
University of PittsburghPatient-Centered Outcomes Research Institute招聘中